No Data
Yabao Pharmaceutical Group, Shanxi University Terminate Technology Transfer Deal
Yabao Pharmaceutical Group (600351.SH): Termination of the technology transfer agreement for Traditional Chinese Medicine new drug projects.
On January 17, Gelonghui reported that Yabao Pharmaceutical Group (600351.SH) announced that on January 17, 2025, due to the "Chai Gui Granule" research and development project not reaching its milestones as scheduled, the company signed a "Class 6 Traditional Chinese Medicine New Drug Chai Gui Granule Project Technical Development Termination Agreement" with Shanxi University. This project termination agreement does not require approval from the company's Board of Directors or Shareholder meeting. After signing the Traditional Chinese Medicine new drug project technical development termination agreement with Shanxi University, the company will strictly fulfill its obligations in accordance with the agreement and closely monitor the implementation of the agreement matters. As of the date of this announcement, the company’s "Chai Gui Granule" project has accumulated.
Yabao Pharmaceutical Group (600351.SH): Obtained the registration certificate for special medical purpose formula food.
On January 17, Gelonghui reported that Yabao Pharmaceutical Group (600351.SH) announced it had received the "Special Medical Purpose Formula Food Registration Certificate" issued by the State Administration for Market Regulation, with the generic name: Special Medical Purpose Protein Component Formula Food, and the commodity name: Weiyuan Jintai. Weiyuan Jintai Special Medical Purpose Protein Component Formula Food is the company's first dual-peptide protein component developed for individuals aged 10 and above who need to supplement protein due to specific diseases or medical conditions.
Yabao Pharmaceutical Group (600351.SH): has accumulated a buyback of 0.75% of its shares.
On December 2, according to Gelonghui, Yabao Pharmaceutical Group (600351.SH) announced that as of November 30, 2024, the company has repurchased a total of 5,419,097 shares through centralized bidding, accounting for 0.75% of the company's total share capital. The highest fill price for the repurchase was 6.56 yuan/share, the lowest fill price was 5.87 yuan/share, and the total amount paid was 33,948,400.49 yuan (excluding transaction fees).
Yabao Pharmaceutical Group Gets Registration Certificate for Oral Solution
Yabao pharmaceutical group (600351.SH): The oral solution of ambroxol has obtained the pharmaceutical registration certificate.
On November 21, Glonghui reported that Yabao Pharmaceutical Group (600351.SH) announced that its wholly-owned subsidiary Yabao Pharmaceutical Sichuan Co., Ltd. has received the Drug Registration Certificate for Ambroxol and Clenbuterol Oral Solution issued by the National Medical Products Administration (certificate number: 2024S02777). Ambroxol and Clenbuterol Oral Solution is a compound preparation mainly consisting of Ambroxol hydrochloride and Clenbuterol hydrochloride, primarily used to relieve symptoms of respiratory diseases. It is suitable for treating cough, viscous phlegm, difficulty in sputum discharge, and wheezing caused by acute and chronic respiratory diseases (such as acute and chronic bronchitis, pulmonary emphysema, etc.).
The Market Doesn't Like What It Sees From Yabao Pharmaceutical Group Co., Ltd's (SHSE:600351) Earnings Yet As Shares Tumble 27%
No Data
